Along with the much heralded guidance requiring coverage of OTC birth control, the Biden Administration also required insurers to cover pre-exposure prophylaxis (PrEP) for prevention of HIV.

With a single drug category and an uncertain political future, the FTC’s legal efforts may gain limited traction. Was focusing on insulin rebating a wisely targeted approach or did the case underemphasize the ‘emotionally more powerful consumer deception issue’?